Table 3 Summary the DVH analysis for the clinical cases of the closed-loop and the two open-loop validations

PTV: V_98% [%]

>90%

97.2 ± 0.9

96.8 ± 1.4

-

NS

[94.9-98.9]

[91.4-98.7]

Normal liver: V_30Gy [%]

<30%

14.7 ± 11.4

14.2 ± 9.6

-

NS

[0.0-51.4]

[0.0-36.8]

Spine: D_1cm3 [Gy]

<45 Gy

15.6 ± 8.0

15.1 ± 9.0

-

<0.05

[3.9-45.3]

[2.7-40.4]

Left kidney V_15Gy [%]

<35%

1.3 ± 6.2

0.6 ± 2.6

-

<0.01

[0.0-39.2]

[0.0-14.6]

Right kidney V_15Gy [%]

<35%

14.3 ± 17.8

8.1 ± 10.8

-

<0.01

[0.0-77.4]

[0.0-39.9]

Stomach V_35Gy [%]

<5%

0.1 ± 0.7

0.1 ± 0.6

-

NS

[0.0-3.3]

[0.0-2.8]

Esophagus: D_1cm3 [Gy]

<60 Gy

25.4 ± 8.5

23.4 ± 8.7

-

<0.10

[12.5-39.9]

[10.4-37.4]

Esophagus: V_30Gy [%]

<30%

0.0 ± 0.0

0.0 ± 0.0

-

NS

[0.0-0.0]

[0.0-0.0]

Validation on the independent sample of 25 patients

Objective

Clinical plans

Open-loop Validation I

Open-loop Validation II

PTV: V_98% [%]

>90%

97.4 ± 0.9

96.8 ± 1.9

97.1 ± 2.6

I: <0.05

[94.9-98.3]

[89.3-98.3]

[89.8-98.6]

II: NS

Normal Liver: V_30Gy [%]

<30%

16.2 ± 10.3

16.9 ± 9.9

18.0 ± 10.5

I: <0.05

[0.0-36.3]

[0.0-35.1]

[0.0-39.5]

II: <0.01

Spine: D_1cm3 [Gy]

<45 Gy

18.7 ± 7.4

17.6 ± 8.2

15.1 ± 5.5

I: <0.01

[4.1-36.0]

[4.3-37.2]

[3.9-25.3]

II: <0.01

Left kidney V_15Gy [%]

<35%

1.4 ± 4.3

0.3 ± 1.4

0.01 ± 0.05

I: <0.01

[0.0-19.6]

[0.0-6.9]

[0.0-0.3]

II: <0.01

Right kidney V_15Gy [%]

<35%

17.6 ± 18.5

12.8 ± 15.0

10.3 ± 10.8

I: <0.01

[0.0-49.9]

[0.0-39.7]

[0.0-34.4]

II: <0.01

Stomach V_35Gy [%]

<5%

0.1 ± 0.3

0.3 ± 1.0

0.0 ± 0.0

I: <0.04

[0.0-0.8]

[0.0-4.2]

[0.0-0.0]

II: NS

Esophagus: D_1cm3 [Gy]

<60 Gy

25.7 ± 9.6

21.9 ± 9.8

17.3 ± 4.7

I: <0.01

[11.9-46.9]

[0.5-46.1]

[10.8-25.1]

II: <0.01

Esophagus: V_30Gy [%]

<30%

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

I: NS

[0.0-0.0]

[0.0-0.0]

[0.0-0.0]

II: NS